Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: ...

FDA Recall #D-0216-2026 — Class II — November 24, 2025

Recall #D-0216-2026 Date: November 24, 2025 Classification: Class II Status: Ongoing

Product Description

Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical Inc., Berkeley Heights, NJ 07922 NDC 51991-748-10.

Reason for Recall

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Recalling Firm

Breckenridge Pharmaceutical, Inc. — Berkeley Heights, NJ

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

7389 bottles

Distribution

Nationwide within the United States

Code Information

Lot #: 240534C, Exp. Date 01/2027; 240977C, Exp. Date 04/2027.

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated